Director of the PhD Programs
Professor and Rotman Chair in
Management
Munk School of Global Affairs, cross appointed
Senior Fellow, Massey College
Rotman School of Management
University of Toronto
105 St. George Street
Toronto, ON, Canada M5S 3E6
(416) 978-6188,
amcgahan@rotman.utoronto.ca
Link to CV
Chief Economist
Senior Institute Associate
Link to Short Bio Division
for Global Health and Human
Rights Institute for
Strategy and Competitiveness
Research Division
of Emergency
Medicine Harvard
Business School
Teaching Massachusetts
General Hospital Institute
webpage: www.isc.hbs.edu
New:
PLEASE CLICK HERE FOR WHAT I DO AND WHY
IM ON BOARD OF UJENZI TRUST, WHICH HAS A REMARKABLE 15-MINUTE VIDEO ABOUT THE SOUTH SUDAN ON ITS WEBPAGE: www.ujenzi.org .
TALK AT TEDxIBYORK ON NOVEMBER 11, 2010 HAS BEEN POSTED HERE. I spoke about why and how I think business schools have to change fundamentally to address the most important management issues of our time.
IM HONORED TO BE PARTICIPATING ON A PANEL ASSESSING CANADA'S STRATEGIC ROLE IN GLOBAL HEALTH. NEWS RELEASE HERE.
I'VE JUST BEEN CROSS APPOINTED TO THE MUNK SCHOOL OF PUBLIC AFFAIRS. An article in the University of Toronto magazine profiles the School and its initiatives. Janice Stein (Munk School), Joe Wong (Munk School), Yu-Ling Cheng (Engineering), Murray Metcalfe (Engineering), Peter Singer (Medicine) and I are involved in an initiative to think more deeply about scaling up and integrative innovation in resource-limited settings.
ARTICLE IN ROTMAN MAGAZINE ON BUSINESS AND HUMAN TRAFFICKING. This article is part of a large project at the Massachusetts General Hospital's Division of Global Health and Human Rights on trafficking in which I'm involved. Under the leadership of the Division's Director, Dr Thomas Burke, the Division has been conducting case studies in eight cities around the world.
WORK WITH COSTAS MARKIDES ON INNOVATION TO CHANGE BUSINESS SYSTEMS. Costas Markides, one of the great scholars in the field of Strategy, is helping me to understand what it takes to write a book that will have an impact on practice. I'm incredibly grateful.
RESEARCH ON INTEGRATED INNOVATION AND HEALTH DELIVERY. With colleagues from the McLaughlin-Rotman Center for Global Health Abdallah Daar and Peter Singer, I've been working on several papers on innovative health delivery models for the poor. Our collaborator and frequent leader in this effort, Onil Bhattacharyya, is a colleague at the University of Toronto's St. Michael's Hospital in the Keenan Research Centre.
RESEARCH ON INDUSTRY INTER-CONNECTEDNESS IN HEALTH. How restrictively designed should medicines and medical devices be? When should scaled up technologies be broadcast globally, and when are localized technologies and practices optimal? How does industry structure inter-relate with the scaling up challenge? With colleagues at Bocconi, I'm working on a project in HIV that takes up these questions.
NEW PROJECT WITH DUKE SCHOLARS NEL DUTT, OLGA HAWN, ELENA VIDAL, RONNIE CHATTERJI and WILL MITCHELL ON BUSINESS INCUBATORS. This fascinating project deals with the difficult issue of what it takes to create markets from scratch in resource-limited settings.
CONTINUING RESEARCH WITH ISIN GULER ON GLOBAL ENTREPRENEURSHIP. We're continuing to invest in a number of papers that address how venture capitalists differentially treat entrepreneurs by country.
MARKET
FOR SUBCONTRACTING SERVICES TO THE MILITARY: Joel Baum and I are working
on a project on this topic.
RECENT ARTICLES WITH PETER KLEIN, JOE MAHONEY AND CHRISTOS PITELIS ON PUBLIC-PRIVATE ENTREPRENEURSHIP. Please see my CV for the full citations. We're interested in understanding how and when innovation in the public interest may occur in the private sector, and the unique challenges of public-private cooperation on public objectives.
MGH TEAM WORKING ON MIGRATION. Thomas Burke, Roy Ahn and I of the Massachusetts General Hospital's Division of Global Health and Human Rights, are co-editing a book on the health of cities in this century.
PLEASE CLICK HERE FOR MY RECENT ARTICLE IN ROTMAN MAGAZINE ON THE END OF OIL
ORGAN TRANSPLANTATION TODAY: In the Health & Human Rights Program at the Massachusetts General Hospital's Center for Global Health, we've been analyzing markets for live organs (mainly kidneys), which are illegal in most places: Our thinking has been sparked by a recent debate in the EU about how these markets can be regulated effectively.
UNDERSTANDING
ENSLAVEMENT, EXPLOITATION AND TRAFFICKING: Thanks to Roy Ahn, Elizabeth
Cafferty and Thomas Burke for leadership in the work we're doing to develop a
better understanding of exploitation and trafficking, particularly of women and
children in resource-limited settings: http://www.massgeneral.org/globalhealth/programs.htm#humanRights
LIMITATIONS
ON THE LIMITED-LIABILITY CORPORATION. Thanks to a generous off-cycle
grant from the Rotman School's AIC Institute for Corporate Citizenship, 15 MBA
students have been working with me, Dr Onil Bhattacharyya of St Michael's
Hospital, and doctoral student Jay Horwitz on alternatives to the
limited-liability corporation for delivering new kinds of products and
services, and especially health services. With Dr Bhattacharyya and
other colleagues from the University of Toronto, we're continuing with a study
of alternative business models for health delivery -- and observing some
innovative and creative solutions already.
TRADE
BETWEEN ADVANCED COUNTRIES, NOT INTO AND OUT OF LEAST-DEVELOPED COUNTRIES,
ESCALATED AFTER TRIPS. Mercedes Delgado, Margaret Kyle and I presented a
paper at the March 2008 NBER Biolocations conference: "The Influence of TRIPS on Global Trade in Pharmaceuticals,
1994-2005." Please send me an email if you're interested in this.
ARE PHARMA COMPANIES DEVELOPING DRUGS FOR NEGLECTED DISEASES? Margaret Kyle and I are working on a paper that analyzes how research on pharmaceuticals adjusted after implementation of the WTO TRIPS agreement, which required patent protections among all WTO member countries, even those designated as "least developed." The policy had the potential to stimulate innovation on neglected diseases, but TRIPS was controversial because it implied high drug prices for poor people. We want to see if the research on neglected diseases is occurring.
HERE'S THE TEXT OF THE IRWIN AWARD TALK THAT I GAVE AT THE ACADEMY IN AUGUST 2010..